Publications by authors named "M Kanitz"
Article Synopsis
- BALB/c mice immunized with adenovirus expressing TSHR developed Graves' disease, and the cyclic peptide P19 was identified as a promising therapy for this condition.
- The study involved analyzing various disease markers and hormone levels in mice over a shortened disease progression period, with P19 administered after initial immunizations.
- Results showed that P19 significantly reduced levels of harmful antibodies and thyroid hormone, while also improving the condition of orbital tissue, suggesting its potential as a novel treatment for Graves' disease and related complications.
Article Synopsis
- A long-term murine model for Graves' disease was developed using repeated immunizations with a recombinant adenovirus, aiming to assess the profile of antibodies targeting the thyrotropin receptor.
- BALB/c mice received multiple doses of either the experimental adenovirus (Ad-TSHR) or a control (Ad-GFP) to analyze the levels and effects of TSHR antibodies (TBAb/TSAb) over time.
- Results indicated that Ad-TSHR-immunized mice showed significantly elevated free thyroxine levels and a high prevalence of TBAb/TSAb, suggesting an effective response to the immunization compared to control mice.
Objective: Stimulating thyrotropin-receptor antibodies (TSAb) cause Graves' disease (GD). We tested a novel homogeneous fluorescent 3',5' cyclic adenine monophosphate (cAMP) assay for the detection of TSAb in a bioassay.
Methods: Chinese hamster ovary (CHO) cell lines expressing either a chimeric (MC4) or wild-type (WT) TSH-R were incubated with the adenyl cyclase activator forskolin, a human TSAb monoclonal antibody (M22), and with sera from GD patients.
Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease.
J Clin Endocrinol Metab
April 2020
Context: Scarce data exist regarding the relevance of stimulatory (TSAb) and blocking (TBAb) thyrotropin receptor antibodies in the management of Graves disease (GD).
Objective: To evaluate the clinical utility and predictive value of TSAb/TBAb.
Design: Prospective 2-year trial.
A rapid and fully automated chemiluminescent immunoassay for the detection of thyrotropin receptor autoantibodies (TSHR-Ab) based on a bridge technology was compared with two bioassays that measure either stimulating (TSAb) or blocking (TBAb) antibodies for the detection and differentiation of TSHR-Ab. A total of 229 patients with various thyroid disorders [151 with Graves' disease (GD), 35 with Hashimoto's thyroiditis (HT), 32 with nodular goiter, and 11 with thyroid cancer] were included. The bridge immunoassay was performed according to the manufacturer's instructions (cut-off>0.
View Article and Find Full Text PDF